



HHS Public Access

Author manuscript

Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2018 February 01.

Published in final edited form as:

Cancer Epidemiol Biomarkers Prev. 2017 February ; 26(2): 270–277. doi:
10.1158/1055-9965.EPI-16-0692.

Differential patterns of risk factors for early-onset breast cancer by ER status in African American women

Kimberly A. Bertrand¹, Traci N. Bethea¹, Lucile L. Adams-Campbell², Lynn Rosenberg¹, and Julie R. Palmer¹

¹Slone Epidemiology Center at Boston University, Boston, MA

²Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC

Abstract

Background—Given the disproportionately high incidence of early-onset breast cancer and aggressive subtypes such as estrogen receptor (ER) negative tumors in African American (AA) women, elucidation of risk factors for early-onset of specific subtypes of breast cancer is needed.

Methods—We evaluated associations of reproductive, anthropometric, and other factors with incidence of invasive breast cancer by age at onset (<45, 45) in 57,708 AA women in the prospective Black Women’s Health Study. From 1995 through 2013, we identified 529 invasive breast cancers among women <45 years of age (151 ER–, 219 ER+) and 1,534 among women 45 years (385 ER–, 804 ER+). We used multivariable Cox proportional hazards regression to estimate hazard ratios (HRs) for associations by age and ER status.

Results—Higher parity, older age at first birth, never having breastfed, and abdominal adiposity were associated with increased risk of early-onset ER– breast cancer: HRs were 1.71 for 3 births versus one birth; 2.29 for first birth after age 25 versus <20 years; 0.61 for ever having breastfed versus never; and 1.64 for highest versus lowest tertile of waist-to-hip ratio. These factors were not associated with ER– cancer in older women or with ER+ cancer regardless of age.

Conclusions—Differences in risk factors by ER subtype were observed for breast cancer diagnosed before age 45.

Impact—Etiological heterogeneity by tumor subtype in early-onset breast cancer, in combination with a higher prevalence of the risk factors in AA women, may explain, in part, racial disparities in breast cancer incidence.

Introduction

While overall breast cancer incidence is similar in African American (AA) and U.S. white women, AA women have a 70% higher incidence of the most aggressive subtypes such as estrogen receptor (ER) negative tumors (1, 2), leading to higher mortality (2). In addition,

Corresponding author: Kimberly A. Bertrand, Slone Epidemiology Center at Boston University, 1010 Commonwealth Avenue, Boston, MA 02215, kab15@bu.edu.

Disclosure of Potential Conflicts of Interest

The authors have no conflicts of interest to disclose.

relative to white women, AA women are more likely to be diagnosed at younger ages (3, 4). Among women ages 20–49, breast cancer mortality rates in the U.S. are now twice as high in AA women compared to white women (14.3 vs. 7.1 per 100,000) (5), underlining the urgent need to understand etiology and identify modifiable risk factors for breast cancer in young AA women.

It has long been recognized that breast cancer is a heterogeneous disease and that epidemiologic risk factors differ in their associations by hormone receptor subtype (6). More recently, based on observed bimodal age distributions in breast cancer incidence, Anderson et al. proposed that early-onset breast cancer, enriched with ER-negative tumors, and later-onset breast cancer, enriched with ER-positive tumors, are etiologically distinct (7–9). We and others have reported differential patterns of associations of several breast cancer risk factors by ER status overall in AA women (10–15), but whether those differences exist for early-onset breast cancer is unknown. Therefore, we assessed the relation of reproductive, anthropometric, and other factors to risk of breast cancer in young women (age <45), overall and by ER status, within the Black Women’s Health Study (BWHS). We conducted similar analyses for women aged 45 and above as a comparison.

Materials and Methods

Study population

The BWHS is an ongoing prospective cohort study of 59,000 AA women (16). In 1995, women ages 21 to 69 years (median age, 38) enrolled in the study by completing a comprehensive self-administered baseline questionnaire. Biennial follow-up questionnaires are mailed to participants to update information on demographic, reproductive, behavioral, and lifestyle factors as well as medication use and medical history. Notices of deaths are obtained from next-of-kin, the U.S. Postal Service, and yearly searches of the National Death Index. Follow-up of the baseline cohort has been successful for 87% of potential person-years.

For this analysis, women were excluded if they had been diagnosed with breast cancer (n=769) or any other type of cancer (except non-melanoma skin cancer) (n=523) before baseline in 1995; the final analytic cohort included 57,708 AA women ages 21–69 at baseline.

The study protocol was approved by the Boston University Institutional Review Board.

Case ascertainment

Incident cases of invasive breast cancer in the BWHS were ascertained through self-report on biennial follow-up questionnaires (95%) or identified through death records and linkage to 24 cancer registries in states covering 95% of participants (5%). Women who reported incident breast cancer were asked for written permission to review their medical records. Study investigators blinded to exposure information reviewed all available medical records and pathology reports, as well as cancer registry data, to confirm breast cancer diagnoses and to abstract data on tumor characteristics. Of cases for which pathology records have been received to date (>80%), more than 99% were confirmed.

Through 2013, we identified 529 incident cases of “early-onset” invasive breast cancer, defined for the purposes of this research as diagnosis before age 45. Of these, 151 cases were classified as ER– and 219 as ER+. Among women ages < 45 years, there were 1,534 incident invasive breast cancers with 385 classified as ER– and 804 as ER+. The distribution of ER status was similar to that reported elsewhere for African American women (17–19). In addition, the distribution of breast cancer risk factors was similar in cases with known and unknown receptor status (20, 21).

Risk factor assessment

The baseline questionnaire collected information on established and putative risk factors for breast cancer including adult height, current weight, waist and hip circumferences, age at menarche, weight at age 18, oral contraceptive use, number and timing of births, duration of lactation, hysterectomy, breast cancer in first-degree relatives, alcohol consumption, cigarette smoking, physical activity, menopausal status, age at menopause, and use of menopausal female hormone supplements. Except for adult height, age at menarche, and weight at age 18, all information was updated on follow-up questionnaires. Self-reports of weight, height, waist circumference, hip circumference, and vigorous physical activity were significantly correlated with objective measures in a validation study (22). Body mass index (BMI) was calculated as weight in kilograms divided by the square of height in meters. We did not assess associations of menopausal status, age at menopause or use of female hormone supplements as risk factors in this report because the vast majority of women <45 years of age were premenopausal and had never used hormone supplements.

Statistical analyses

We used the Andersen-Gill data structure (23), with one record per woman per 2-year questionnaire cycle, to allow for time-varying risk factors and survival analysis with time at risk as the underlying timescale. Women contributed person-years from the beginning of follow-up in March, 1995 until diagnosis of breast cancer, death, loss to follow-up, or end of follow-up in March, 2013, whichever occurred first, for a total of 881,204 person years. We used multivariable Cox proportional hazards regression models, stratified by age in one-year intervals and questionnaire cycle, to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for risk of overall, ER–, and ER+ breast cancer, separately, in relation to each factor listed above. All analyses were stratified by age (<45 and ≥45) to compare associations for early- vs. later-onset breast cancer and all models were mutually adjusted for all risk factors as well as smoking history, menopausal status and, for older women, age at menopause and duration of combination (estrogen plus progestin) menopausal hormone supplement use. HRs for age at first birth, time since last birth, and lactation were estimated from models fit among parous women only. Time-varying risk factors were updated at each questionnaire cycle. Missing indicator categories were used to account for missing information in risk factors (generally 2–4%). To test whether the risk factor associations differed by ER status within each age group, we used the contrast test method for heterogeneity by subtype (24). Finally, we evaluated statistical interaction of risk factors with age using a likelihood ratio test, comparing main-effects only models with models including cross-product terms for age (<45 vs. ≥45) and each categorical risk factor. All analyses were performed using SAS 9.4 (Cary, North Carolina).

Results

Compared with breast cancers diagnosed at age 45 and older, cancers that occurred in women under age 45 were more likely to be ER- (41% vs. 32%) and to have other aggressive tumor features, such as advanced stage of disease (regional or distant, 50% vs. 35%), higher grade (poorly differentiated or undifferentiated, 57% vs. 46%), and larger tumor size (>2 cm, 47% vs. 34%) (Table 1). Characteristics of the study population according to age group are available in the Supplementary Table. Other characteristics of the overall study population at baseline have been presented elsewhere (25, 26).

Associations of known and suspected breast cancer risk factors with incidence of breast cancer before age 45, overall and by ER subtype, are shown in Table 2. Family history of breast cancer, early age at menarche, recent oral contraceptive use, and pregnancy within the previous 10 years were associated with increased risk of both subtypes, and higher BMI at age 18 was associated with reduced risk of both subtypes. Other associations differed by ER subtype: breastfeeding was associated with a reduced risk of ER- breast cancer [HR (95% CI): 0.61 (0.40, 0.92)] but was not associated with ER+ breast cancer; high parity was associated with increased risk of ER- cancer [1.71 (0.98, 2.99)] but with a reduced risk of ER+ cancer [0.69 (0.41, 1.14)]; and late age at first birth was associated with increased risk of ER- cancer [2.29 (1.32, 3.97)] but not ER+ cancer (p-heterogeneity <0.05 for each of the three factors). There was also significant heterogeneity in the results for waist-to-hip ratio, with a 64% increased risk of ER- breast cancer for women in the top relative to the bottom tertile (95% CI: 1.04, 2.59) and no apparent increase in risk of ER+ breast cancer.

Results from analyses of women ≥ 45 years of age are shown in Table 3. BMI ≥ 25 kg/m² at age 18 was associated with decreased risk, while family history of breast cancer, early age at menarche, and recent oral contraceptive use were associated with increased risk of both ER- and ER+ breast cancer. HRs for nulliparity relative to one birth were 0.71 (0.48, 1.07) for ER- breast cancer and 1.17 (0.90, 1.52) for ER+ cancer (p-heterogeneity = 0.05). The other factors examined were not associated with breast cancer risk in women over 45, regardless of ER subtype. In fact, the lack of association for high waist-to-hip ratio with risk of ER- breast cancer in women age 45 and older was in contrast to the strong positive association observed among younger women (p-interaction = 0.03).

As noted, having a first degree family history of breast cancer was associated with increased risk of breast cancer in both age groups and for both ER subtypes; however, the positive association was significantly stronger in the younger women (p-interaction = 0.02).

Discussion

In this large prospective cohort study of African American women, we identified breast cancer risk factor profiles that differed by age at diagnosis and ER status. Higher parity, older age at first birth, never having breastfed, and greater abdominal adiposity were important risk factors for early-onset ER- breast cancer. These factors were not associated with increased risk of later-onset ER- breast cancer or with ER+ cancers in either age group. Other factors were associated with both ER- and ER+ breast cancer, regardless of age.

In a recent case-control study in Seattle-Puget Sound with approximately 1,000 breast cancer cases diagnosed before age 45, Li et al. reported that parity was associated with reductions in risk of both ER+ and “triple-negative” tumors and that increasing number of live births was similarly associated with reduced risk of both subtypes (27). Non-Hispanic white women comprised approximately 80% of that study population. In contrast, in an analysis of reproductive factors and premenopausal breast cancer diagnosed before age 40 in the predominantly white Nurses’ Health Studies (NHS), Warner et al. found a non-significant inverse association of parity with ER+/PR+ breast cancer (n=118) but a suggestive positive association with ER-/PR- breast cancer (n=71) (28). In the present study of AA women diagnosed before age 45, we found that higher parity was associated with increased risk of ER- breast cancers. The present analysis updates our earlier reports of parity and lactation in relation to breast cancer in the BWHS (20, 29), and is also consistent with findings of a recent large pooled analysis of AA women, which included the BWHS, in which parity relative to nulliparity was associated with increased risk of ER- breast cancer with risk increasing with number of births (12). While increased risks for parous versus nulliparous were observed across age strata, the association appeared stronger for early-onset ER- disease, consistent with the current findings. Breastfeeding was associated with reduced risk of early-onset ER- breast cancer in the present study, consistent with our earlier reports (20, 29) with findings from the NHS (28) and with the Seattle-Puget Sound study (27).

Older age at first birth has been fairly consistently positively associated with ER+ breast cancer (30–34), and this association has been observed among both younger and older women (28, 31–33, 35, 36). While we observed a weak positive association for later-onset ER+ breast cancer, we found no apparent association between age at first birth and risk of early-onset ER+ breast cancer. For overall ER- breast cancer, most previous studies have shown no clear association with age at first birth (31, 32), while results from studies in young women have been mixed, with reports of positive (28, 37), inverse (27, 36), and null associations (35, 38). In the current analysis, we found that later age at first birth was associated with more than twice the risk of early-onset ER- breast cancer, but not later-onset ER- cancer. These findings suggest that non-hormonal mechanisms of carcinogenesis may contribute to the associations with ER-breast cancer, which may be particularly relevant for younger women.

We also observed a positive association of waist-to-hip ratio with early-onset ER- breast cancer. The existing literature on central adiposity and breast cancer risk, is not consistent (17, 39–47). In the Nurses’ Health Study II, Harris et al. reported a significant 2-fold increased risk of ER- breast cancer (n=131) for women in the highest quintile of waist-to-hip ratio compared to the lowest, after adjustment for BMI (40); similar positive associations with ER- disease were observed in a U.S. case-control study (48) and a Finnish case-control study (49). Other studies in premenopausal white or multiethnic populations, however, found no associations (37, 43, 50). Current findings from the BWHS are consistent with results from the Carolina Breast Cancer Study (CBCS) (17) and the Women’s Circle of Health Study (WCHS) (41), both of which reported increased risk of premenopausal ER- breast cancer in AA women associated with measures of central adiposity (e.g., waist circumference and waist-to-hip ratio).

There is consistent evidence that higher BMI in young adulthood is associated with decreased risk of both pre- and postmenopausal breast cancer (51–60), although few studies have examined this association by age at onset (52, 61–63) or ER status (57, 58, 63). In the present study, we found strong inverse associations of BMI at age 18 with both ER– and ER+ breast cancer diagnosed before age 45. These findings are consistent with results from other studies of younger women that evaluated overall breast cancer (52, 61, 62). In the Seattle-Puget Sound study, there was a non-significant inverse association of BMI at age 18 with risk of triple-negative breast cancer (OR: 0.7; 95% CI: 0.4, 1.2) but no association with ER+ breast cancer (63). While the mechanisms underlying the association between BMI in young adulthood and breast cancer risk are not well understood, proposed hypotheses include less cumulative exposure to endogenous estrogens due to anovulatory cycles in overweight women (64), faster clearance of free estradiol by the liver in overweight women (65), or greater susceptibility to carcinogenic influences in lean women.

Some limitations of this study are worth noting. First, while we were interested in identifying risk factors for early-onset ER– and ER+ breast cancer in AA women, and comparing them to factors associated with breast cancer in older women, we may have been underpowered to detect significant interactions by age. Second, while we had nearly complete data for most risk factors of interest (generally ~2% missing data), there was a fair amount of missing data for waist-to-hip ratio (16%), which required participants to have a tape measure on hand. Third, we did not have information on ER status for 24% of cases; however, the risk factor distribution was similar in cases with and without known ER status, suggesting that any potential selection bias is likely small. We were not able to evaluate associations with triple-negative breast cancer due to small numbers, once we stratified by age.

Despite some limitations, the strengths of this study are considerable, including the prospective design, the large sample size with high follow-up, and high accuracy of reporting of breast cancer diagnoses and risk factor information. Because of the availability of detailed questionnaire data, we were able to perform multivariable analyses including established and suspected risk factors for breast cancer to account for potential confounding. Most importantly, there are very few studies of breast cancer in AA women and even fewer that are able to evaluate risk factors in younger AA women. We have reported on many of the risk factors evaluated in prior analyses (20, 21, 56, 66–68). Now, with the accrual of sufficient numbers of breast cancer cases in the BWHS, the current analysis represents the first study to prospectively characterize risk factor profiles for early-onset ER– and ER+ breast cancer in AA women.

Differential associations of risk factors by age for ER– and ER+ breast cancers in AA women suggest etiological heterogeneity by tumor subtype and are supportive of the hypotheses by Anderson et al. of age-specific subtypes (7–9). Higher parity, never having breastfed, and abdominal adiposity were associated with increased risk of early-onset ER– breast cancer but not with later onset ER– or with ER+ cancer regardless of age. The distribution of these risk factors differs appreciably between AA and white women: AA women tend to have higher parity (69, 70), lower rates of breastfeeding (71–73), and greater abdominal adiposity (74). Therefore, these differences could explain, in part, disparities in

breast cancer incidence between AA and white women, especially for younger women. Some of the identified risk factors, including lactation and higher waist-to-hip ratio, are potentially modifiable, suggesting opportunities for prevention.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported by the National Institutes of Health (CA058420 to L. Rosenberg, J.R. Palmer, and LL Adams-Campbell; CA164974 to L. Rosenberg, J.R. Palmer, and LL Adams-Campbell; CA151135 to J.R. Palmer; and CA182898 to J.R. Palmer). Data on breast cancer pathology were obtained from several state cancer registries (AZ, CA, CO, CT, DE, DC, FL, GA, IL, IN, KY, LA, MD, MA, MI, NJ, NY, NC, OK, PA, SC, TN, TX, VA). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute, the National Institutes of Health or the state cancer registries. We thank participants and staff of the Black Women's Health Study for their contributions.

References

1. Kohler BA, Sherman RL, Howlander N, Jemal A, Ryerson AB, Henry KA, et al. Annual Report to the Nation on the Status of Cancer, 1975–2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State. *J Natl Cancer Inst.* 2015; 107:djv048. [PubMed: 25825511]
2. DeSantis CE, Fedewa SA, Goding Sauer A, Kramer JL, Smith RA, Jemal A. Breast cancer statistics, 2015: Convergence of incidence rates between black and white women. *CA Cancer J Clin.* 2016; 66:31–42. [PubMed: 26513636]
3. Clarke CA, Keegan TH, Yang J, Press DJ, Kurian AW, Patel AH, et al. Age-specific incidence of breast cancer subtypes: understanding the black-white crossover. *J Natl Cancer Inst.* 2012; 104:1094–1101. [PubMed: 22773826]
4. Anderson WF, Rosenberg PS, Menashe I, Mitani A, Pfeiffer RM. Age-related crossover in breast cancer incidence rates between black and white ethnic groups. *J Natl Cancer Inst.* 2008; 100:1804–1814. [PubMed: 19066264]
5. McCarthy AM, Yang J, Armstrong K. Increasing disparities in breast cancer mortality from 1979 to 2010 for US black women aged 20 to 49 years. *Am J Public Health.* 2015; 105(Suppl 3):S446–448. [PubMed: 25905842]
6. Potter JD, Cerhan JR, Sellers TA, McGovern PG, Drinkard C, Kushi LR, et al. Progesterone and estrogen receptors and mammary neoplasia in the Iowa Women's Health Study: how many kinds of breast cancer are there? *Cancer Epidemiol Biomarkers Prev.* 1995; 4:319–326. [PubMed: 7655325]
7. Anderson WF, Chu KC, Chang S, Sherman ME. Comparison of age-specific incidence rate patterns for different histopathologic types of breast carcinoma. *Cancer Epidemiol Biomarkers Prev.* 2004; 13:1128–1135. [PubMed: 15247123]
8. Anderson WF, Pfeiffer RM, Dores GM, Sherman ME. Comparison of age distribution patterns for different histopathologic types of breast carcinoma. *Cancer Epidemiol Biomarkers Prev.* 2006; 15:1899–1905. [PubMed: 17035397]
9. Anderson WF, Rosenberg PS, Prat A, Perou CM, Sherman ME. How many etiological subtypes of breast cancer: two, three, four, or more? *J Natl Cancer Inst.* 2014:106.
10. Ambrosone CB, Zirpoli G, Hong CC, Yao S, Troester MA, Bandera EV, et al. Important Role of Menarche in Development of Estrogen Receptor-Negative Breast Cancer in African American Women. *J Natl Cancer Inst.* 2015:107.
11. Bandera EV, Chandran U, Hong CC, Troester MA, Bethea TN, Adams-Campbell LL, et al. Obesity, body fat distribution, and risk of breast cancer subtypes in African American women participating in the AMBER Consortium. *Breast Cancer Res Treat.* 2015; 150:655–666. [PubMed: 25809092]

12. Palmer JR, Viscidi E, Troester MA, Hong CC, Schedin P, Bethea TN, et al. Parity, lactation, and breast cancer subtypes in African American women: results from the AMBER Consortium. *J Natl Cancer Inst.* 2014;106.
13. Work ME, John EM, Andrulis IL, Knight JA, Liao Y, Mulligan AM, et al. Reproductive risk factors and oestrogen/progesterone receptor-negative breast cancer in the Breast Cancer Family Registry. *Br J Cancer.* 2014; 110:1367–1377. [PubMed: 24548865]
14. Li CI, Malone KE, Daling JR, Potter JD, Bernstein L, Marchbanks PA, et al. Timing of menarche and first full-term birth in relation to breast cancer risk. *Am J Epidemiol.* 2008; 167:230–239. [PubMed: 17965112]
15. Colditz GA, Rosner BA, Chen WY, Holmes MD, Hankinson SE. Risk factors for breast cancer according to estrogen and progesterone receptor status. *J Natl Cancer Inst.* 2004; 96:218–228. [PubMed: 14759989]
16. Rosenberg L, Adams-Campbell L, Palmer JR. The Black Women's Health Study: a follow-up study for causes and preventions of illness. *J Am Med Womens Assoc.* 1995; 50:56–58.
17. Robinson WR, Tse CK, Olshan AF, Troester MA. Body size across the life course and risk of premenopausal and postmenopausal breast cancer in Black women, the Carolina Breast Cancer Study, 1993–2001. *Cancer Causes Control.* 2014; 25:1101–1117. [PubMed: 24924530]
18. Cui Y, Deming-Halverson SL, Shrubsole MJ, Beeghly-Fadiel A, Fair AM, Sanderson M, et al. Associations of hormone-related factors with breast cancer risk according to hormone receptor status among white and African American women. *Clin Breast Cancer.* 2014; 14:417–425. [PubMed: 24970715]
19. Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. *J Natl Cancer Inst.* 2014;106.
20. Palmer JR, Boggs DA, Wise LA, Ambrosone CB, Adams-Campbell LL, Rosenberg L. Parity and lactation in relation to estrogen receptor negative breast cancer in African American women. *Cancer Epidemiol Biomarkers Prev.* 2011; 20:1883–1891. [PubMed: 21846820]
21. Rosenberg L, Boggs DA, Wise LA, Adams-Campbell LL, Palmer JR. Oral contraceptive use and estrogen/progesterone receptor-negative breast cancer among African American women. *Cancer Epidemiol Biomarkers Prev.* 2010; 19:2073–2079. [PubMed: 20647407]
22. Carter-Nolan PL, Adams-Campbell LL, Makambi K, Lewis S, Palmer JR, Rosenberg L. Validation of physical activity instruments: Black Women's Health Study. *Ethn Dis.* 2006; 16:943–947. [PubMed: 17061751]
23. Andersen PK, Gill RD. Cox Regression-Model for Counting-Processes - a Large Sample Study. *Annals of Statistics.* 1982; 10:1100–1120.
24. Wang ML, Spiegelman D, Kuchiba A, Lochhead P, Kim S, Chan AT, et al. Statistical methods for studying disease subtype heterogeneity. *Statistics in Medicine.* 2016; 35:782–800. [PubMed: 26619806]
25. Palmer JR, Wise LA, Adams-Campbell LL, Rosenberg L. A prospective study of induced abortion and breast cancer in African-American women. *Cancer Causes Control.* 2004; 15:105–111. [PubMed: 15017122]
26. Rosenberg L, Palmer JR, Wise LA, Adams-Campbell LL. A prospective study of female hormone use and breast cancer among black women. *Arch Intern Med.* 2006; 166:760–765. [PubMed: 16606813]
27. Li CI, Beaber EF, Tang MT, Porter PL, Daling JR, Malone KE. Reproductive factors and risk of estrogen receptor positive, triple-negative, and HER2-neu overexpressing breast cancer among women 20–44 years of age. *Breast Cancer Res Treat.* 2013; 137:579–587. [PubMed: 23224237]
28. Warner ET, Colditz GA, Palmer JR, Partridge AH, Rosner BA, Tamimi RM. Reproductive factors and risk of premenopausal breast cancer by age at diagnosis: are there differences before and after age 40? *Breast Cancer Res Treat.* 2013; 142:165–175. [PubMed: 24136668]
29. Palmer JR, Wise LA, Horton NJ, Adams-Campbell LL, Rosenberg L. Dual effect of parity on breast cancer risk in African-American women. *J Natl Cancer Inst.* 2003; 95:478–483. [PubMed: 12644541]
30. Anderson KN, Schwab RB, Martinez ME. Reproductive risk factors and breast cancer subtypes: a review of the literature. *Breast Cancer Res Treat.* 2014; 144:1–10. [PubMed: 24477977]

31. Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, Milne RL, et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. *J Natl Cancer Inst.* 2011; 103:250–263. [PubMed: 21191117]
32. Ma H, Bernstein L, Pike MC, Ursin G. Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. *Breast Cancer Res.* 2006; 8:R43. [PubMed: 16859501]
33. Ritte R, Tikk K, Lukanova A, Tjonneland A, Olsen A, Overvad K, et al. Reproductive factors and risk of hormone receptor positive and negative breast cancer: a cohort study. *BMC Cancer.* 2013; 13:584. [PubMed: 24321460]
34. Sisti JS, Collins LC, Beck AH, Tamimi RM, Rosner BA, Eliassen AH. Reproductive risk factors in relation to molecular subtypes of breast cancer: Results from the nurses' health studies. *Int J Cancer.* 2016; 138:2346–2356. [PubMed: 26684063]
35. McCredie MR, Dite GS, Southey MC, Venter DJ, Giles GG, Hopper JL. Risk factors for breast cancer in young women by oestrogen receptor and progesterone receptor status. *Br J Cancer.* 2003; 89:1661–1663. [PubMed: 14583766]
36. Ma H, Bernstein L, Ross RK, Ursin G. Hormone-related risk factors for breast cancer in women under age 50 years by estrogen and progesterone receptor status: results from a case-control and a case-case comparison. *Breast Cancer Res.* 2006; 8:R39. [PubMed: 16846528]
37. Britton JA, Gammon MD, Schoenberg JB, Stanford JL, Coates RJ, Swanson CA, et al. Risk of breast cancer classified by joint estrogen receptor and progesterone receptor status among women 20–44 years of age. *Am J Epidemiol.* 2002; 156:507–516. [PubMed: 12225998]
38. Cotterchio M, Kreiger N, Theis B, Sloan M, Bahl S. Hormonal factors and the risk of breast cancer according to estrogen- and progesterone-receptor subgroup. *Cancer Epidemiol Biomarkers Prev.* 2003; 12:1053–1060. [PubMed: 14578142]
39. Tehard B, Clavel-Chapelon F. Several anthropometric measurements and breast cancer risk: results of the E3N cohort study. *Int J Obes (Lond).* 2006; 30:156–163. [PubMed: 16231021]
40. Harris HR, Willett WC, Terry KL, Michels KB. Body fat distribution and risk of premenopausal breast cancer in the Nurses' Health Study II. *J Natl Cancer Inst.* 2011; 103:273–278. [PubMed: 21163903]
41. Bandera EV, Chandran U, Zirpoli G, Gong Z, McCann SE, Hong CC, et al. Body fatness and breast cancer risk in women of African ancestry. *BMC Cancer.* 2013; 13:475. [PubMed: 24118876]
42. Lahmann PH, Hoffmann K, Allen N, van Gils CH, Khaw KT, Tehard B, et al. Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer And Nutrition (EPIC). *Int J Cancer.* 2004; 111:762–771. [PubMed: 15252848]
43. Ritte R, Lukanova A, Berrino F, Dossus L, Tjonneland A, Olsen A, et al. Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study. *Breast Cancer Res.* 2012; 14:R76. [PubMed: 22583394]
44. White AJ, Nichols HB, Bradshaw PT, Sandler DP. Overall and central adiposity and breast cancer risk in the Sister Study. *Cancer.* 2015; 121:3700–3708. [PubMed: 26193782]
45. Amadou A, Ferrari P, Muwonge R, Moskal A, Biessy C, Romieu I, et al. Overweight, obesity and risk of premenopausal breast cancer according to ethnicity: a systematic review and dose-response meta-analysis. *Obes Rev.* 2013; 14:665–678. [PubMed: 23615120]
46. Connolly BS, Barnett C, Vogt KN, Li T, Stone J, Boyd NF. A meta-analysis of published literature on waist-to-hip ratio and risk of breast cancer. *Nutr Cancer.* 2002; 44:127–138. [PubMed: 12734058]
47. Ogundiran TO, Huo D, Adenipekun A, Campbell O, Oyeseun R, Akang E, et al. Body fat distribution and breast cancer risk: findings from the Nigerian breast cancer study. *Cancer Causes Control.* 2012; 23:565–574. [PubMed: 22367701]
48. Slattery ML, Sweeney C, Edwards S, Herrick J, Baumgartner K, Wolff R, et al. Body size, weight change, fat distribution and breast cancer risk in Hispanic and non-Hispanic white women. *Breast Cancer Res Treat.* 2007; 102:85–101. [PubMed: 17080310]

49. Mannisto S, Pietinen P, Pyy M, Palmgren J, Eskelinen M, Uusitupa M. Body-size indicators and risk of breast cancer according to menopause and estrogen-receptor status. *Int J Cancer*. 1996; 68:8–13. [PubMed: 8895532]
50. John EM, Sangaramoorthy M, Phipps AI, Koo J, Horn-Ross PL. Adult body size, hormone receptor status, and premenopausal breast cancer risk in a multiethnic population: the San Francisco Bay Area breast cancer study. *Am J Epidemiol*. 2011; 173:201–216. [PubMed: 21084558]
51. Magnusson C, Baron J, Persson I, Wolk A, Bergstrom R, Trichopoulos D, et al. Body size in different periods of life and breast cancer risk in post-menopausal women. *Int J Cancer*. 1998; 76:29–34. [PubMed: 9533758]
52. Peacock SL, White E, Daling JR, Voigt LF, Malone KE. Relation between obesity and breast cancer in young women. *Am J Epidemiol*. 1999; 149:339–346. [PubMed: 10025476]
53. Morimoto LM, White E, Chen Z, Chlebowski RT, Hays J, Kuller L, et al. Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States). *Cancer Causes Control*. 2002; 13:741–751. [PubMed: 12420953]
54. Weiderpass E, Braaten T, Magnusson C, Kumle M, Vainio H, Lund E, et al. A prospective study of body size in different periods of life and risk of premenopausal breast cancer. *Cancer Epidemiol Biomarkers Prev*. 2004; 13:1121–1127. [PubMed: 15247122]
55. Michels KB, Terry KL, Willett WC. Longitudinal study on the role of body size in premenopausal breast cancer. *Arch Intern Med*. 2006; 166:2395–2402. [PubMed: 17130395]
56. Palmer JR, Adams-Campbell LL, Boggs DA, Wise LA, Rosenberg L. A prospective study of body size and breast cancer in black women. *Cancer Epidemiol Biomarkers Prev*. 2007; 16:1795–1802. [PubMed: 17855697]
57. Suzuki R, Iwasaki M, Inoue M, Sasazuki S, Sawada N, Yamaji T, et al. Body weight at age 20 years, subsequent weight change and breast cancer risk defined by estrogen and progesterone receptor status--the Japan public health center-based prospective study. *Int J Cancer*. 2011; 129:1214–1224. [PubMed: 21064092]
58. John EM, Sangaramoorthy M, Hines LM, Stern MC, Baumgartner KB, Giuliano AR, et al. Body size throughout adult life influences postmenopausal breast cancer risk among hispanic women: the breast cancer health disparities study. *Cancer Epidemiol Biomarkers Prev*. 2015; 24:128–137. [PubMed: 25352523]
59. Bandera EV, Maskarinec G, Romieu I, John EM. Racial and ethnic disparities in the impact of obesity on breast cancer risk and survival: a global perspective. *Adv Nutr*. 2015; 6:803–819. [PubMed: 26567202]
60. Xue F, Rosner B, Eliassen H, Michels KB. Body fatness throughout the life course and the incidence of premenopausal breast cancer. *Int J Epidemiol*. 2016
61. Brinton LA, Swanson CA. Height and weight at various ages and risk of breast cancer. *Ann Epidemiol*. 1992; 2:597–609. [PubMed: 1342311]
62. Swerdlow AJ, De Stavola BL, Floderus B, Holm NV, Kaprio J, Verkasalo PK, et al. Risk factors for breast cancer at young ages in twins: an international population-based study. *J Natl Cancer Inst*. 2002; 94:1238–1246. [PubMed: 12189227]
63. Kawai M, Malone KE, Tang MT, Li CI. Height, body mass index (BMI), BMI change, and the risk of estrogen receptor-positive, HER2-positive, and triple-negative breast cancer among women ages 20 to 44 years. *Cancer*. 2014; 120:1548–1556. [PubMed: 24500704]
64. Key TJ, Pike MC. The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer. *Eur J Cancer Clin Oncol*. 1988; 24:29–43. [PubMed: 3276531]
65. Potischman N, Swanson CA, Siiteri P, Hoover RN. Reversal of relation between body mass and endogenous estrogen concentrations with menopausal status. *J Natl Cancer Inst*. 1996; 88:756–758. [PubMed: 8637031]
66. Palmer JR, Boggs DA, Adams-Campbell LL, Rosenberg L. Family history of cancer and risk of breast cancer in the Black Women's Health Study. *Cancer Causes Control*. 2009; 20:1733–1737. [PubMed: 19760028]

67. Rosenberg L, Palmer JR, Bethea TN, Ban Y, Kipping-Ruane K, Adams-Campbell LL. A prospective study of physical activity and breast cancer incidence in African-American women. *Cancer Epidemiol Biomarkers Prev.* 2014; 23:2522–2531. [PubMed: 25103823]
68. Boggs DA, Rosenberg L, Adams-Campbell LL, Palmer JR. Prospective approach to breast cancer risk prediction in African American women: the black women's health study model. *J Clin Oncol.* 2015; 33:1038–1044. [PubMed: 25624428]
69. Martin JA, Hamilton BE, Osterman MJ, Curtin SC, Matthews TJ. Births: final data for 2013. *Natl Vital Stat Rep.* 2015; 64:1–65.
70. Martinez G, Daniels K, Chandra A. Fertility of men and women aged 15–44 years in the United States: National Survey of Family Growth, 2006–2010. *National health statistics reports.* 2012:1–28.
71. Centers for Disease Control and Prevention. Progress in increasing breastfeeding and reducing racial/ethnic differences - United States, 2000–2008 births. *MMWR Morb Mortal Wkly Rep.* 2013; 62:77–80. [PubMed: 23388550]
72. Jones KM, Power ML, Queenan JT, Schulkin J. Racial and ethnic disparities in breastfeeding. *Breastfeed Med.* 2015; 10:186–196. [PubMed: 25831234]
73. McDowell MM, Wang CY, Kennedy-Stephenson J. Breastfeeding in the United States: findings from the national health and nutrition examination surveys, 1999–2006. *NCHS Data Brief.* 2008:1–8.
74. Ford ES, Maynard LM, Li C. Trends in mean waist circumference and abdominal obesity among US adults, 1999–2012. *JAMA.* 2014; 312:1151–1153. [PubMed: 25226482]

Table 1

Breast cancer tumor characteristics by age.

	<u>Age <45 (n=529)</u>		<u>Age ≥45 (n=1,534)</u>	
	<i>n</i>	%	<i>n</i>	%
ER status				
Positive	219	59.2%	804	67.6%
Negative	151	40.8%	385	32.4%
SEER stage				
Localized	225	49.7%	832	64.6%
Regional	211	46.6%	401	31.1%
Distant	17	3.8%	55	4.3%
Grade				
Well-differentiated	36	8.5%	187	15.2%
Moderately differentiated	146	34.4%	473	38.4%
Poorly or undifferentiated	243	57.2%	571	46.4%
Tumor size				
1.0 cm	81	19.8%	339	27.7%
>1–2.0 cm	135	32.9%	474	38.7%
>2 cm	194	47.3%	411	33.6%

ER status was unknown or missing for 159 cases <45 years and 345 cases ≥45 years; SEER stage was unknown or missing for 76 cases <45 years and 246 cases ≥45 years; grade was unknown or missing for 104 cases <45 years and 303 cases ≥45 years; tumor size was missing for 119 cases <45 years and 310 cases ≥45 years.

Table 2

Multivariable analyses for associations of risk factors with invasive BC among women age <45 years, by ER status.*

	All invasive (n=529)			ER- (n=151)			ER+ (n=219)			
	person-years	HR	95% CI	cases	HR	95% CI	cases	HR	95% CI	
Age at menarche (yrs)										
11	124,385	1.00	reference	53	1.00	reference	75	1.00	reference	
12-13	221,987	0.86	0.71 1.04	72	0.73	0.51 1.04	110	0.79	0.58 1.06	
14	73,990	83	0.73 0.56 0.96	25	0.70	0.43 1.13	32	0.67	0.44 1.01	
Oral contraceptive use										
Never	70,615	79	1.00	reference	19	1.00	reference	29	1.00	reference
Ever, 10 yrs ago	116,719	180	0.93	0.71 1.21	54	1.21	0.71 2.07	74	1.02	0.66 1.58
Ever, 5-10 yrs ago	63,872	82	1.07	0.78 1.46	19	1.03	0.54 1.97	34	1.12	0.67 1.85
Ever, within 5 yrs	171,110	188	1.25	0.95 1.64	59	1.53	0.90 2.62	82	1.40	0.90 2.16
Family history of breast cancer										
No	397,064	456	1.00	reference	131	1.00	reference	190	1.00	reference
Yes	25,280	73	2.27	1.77 2.90	20	2.11	1.32 3.39	29	2.16	1.46 3.20
Parity										
Nulliparous	163,006	156	1.11	0.80 1.55	43	1.30	0.69 2.47	68	0.90	0.54 1.48
1 birth	111,372	148	1.00	reference	40	1.00	reference	72	1.00	reference
2 births	90,252	135	1.07	0.84 1.37	40	1.30	0.82 2.05	51	0.80	0.54 1.16
3 births	54,927	90	1.21	0.89 1.64	28	1.71	0.98 2.99	28	0.69	0.41 1.14
Age at first birth (yrs) ^d										
<20	64,929	86	1.00	reference	22	1.00	reference	35	1.00	reference
20-24	76,126	92	1.01	0.74 1.36	28	1.42	0.80 2.50	28	0.65	0.39 1.09
25	110,113	190	1.44	1.08 1.94	58	2.29	1.32 3.97	85	1.06	0.67 1.67
Years since last birth ^d										
10 yrs	114,915	186	1.00	reference	54	1.00	reference	75	1.00	reference
<10 yrs	132,817	178	1.43	1.13 1.81	53	1.39	0.90 2.16	72	1.44	1.00 2.07
Lactation ^d										
Never	133,107	199	1.00	reference	64	1.00	reference	70	1.00	reference

	All invasive (n=529)			ER- (n=151)			ER+ (n=219)		
	person-years	cases	HR 95% CI	cases	HR 95% CI	cases	HR 95% CI		
Ever	121,551	174	0.87 0.70 1.08	44	0.61 0.40 0.92	81	1.22 0.87 1.73		
BMI at age 18 (kg/m ²)									
<20	152,177	216	1.00 reference	69	1.00 reference	87	1.00 reference		
20–24	192,897	259	0.97 0.80 1.18	62	0.68 0.47 0.99	111	1.04 0.77 1.41		
25	71,914	49	0.51 0.36 0.72	19	0.55 0.31 0.99	21	0.52 0.31 0.88		
Current BMI (kg/m ²)									
<25	147,559	168	1.00 reference	40	1.00 reference	73	1.00 reference		
25–29.9	125,668	174	1.03 0.83 1.29	57	1.47 0.97 2.25	63	0.87 0.62 1.24		
30	145,616	183	1.04 0.81 1.33	53	1.24 0.76 2.01	83	1.10 0.76 1.60		
Waist:hip ratio									
Tertile 1 (<0.76)	113,945	123	1.00 reference	33	1.00 reference	55	1.00 reference		
Tertile 2 (0.76–0.84)	102,018	114	1.00 0.77 1.29	28	0.89 0.54 1.48	53	1.00 0.68 1.47		
Tertile 3 (>0.84)	101,901	141	1.30 1.01 1.68	50	1.64 1.04 2.59	45	0.88 0.58 1.33		
Alcohol consumption (drinks)									
<1/wk	300,559	372	1.00 reference	114	1.00 reference	151	1.00 reference		
1–6/wk	104,727	130	0.96 0.78 1.18	29	0.69 0.46 1.05	56	0.94 0.69 1.29		
7/wk	16,542	27	1.28 0.86 1.91	5	0.73 0.30 1.83	12	1.39 0.76 2.55		
Vigorous exercise									
None	155,744	211	1.00 reference	64	1.00 reference	86	1.00 reference		
<5 hrs/week	215,857	258	0.96 0.80 1.16	73	0.97 0.69 1.37	110	0.93 0.28 3.02		
5 hrs/week	47,631	55	1.00 0.74 1.35	13	0.87 0.47 1.59	23	1.00 0.75 1.33		

* Multivariable hazards ratios (HRs) adjusted for age, smoking history (never active or passive, passive only, never active/unknown passive, 1–<10 packyears, 10+ packyears), menopausal status (premenopausal, hysterectomy only, postmenopausal, missing), and all factors in Table 2.

^a Among parous women only. Estimates for age at first birth adjusted for age, smoking history, menopausal status, and all factors in Table 2 except years since last birth; estimates for years since last birth adjusted for age, smoking history, menopausal status, and all factors in Table 2 except age at first birth; estimates for lactation adjusted for age, smoking history, menopausal status, and all factors in Table 2.

Table 3
 Multivariable analyses for associations of risk factors with invasive BC among women age 45 years, by ER status.*

	All invasive (n=1,534)			ER- (n=385)			ER+ (n=804)		
	person-years	HR	95% CI	cases	HR	95% CI	cases	HR	95% CI
Age at menarche (yrs)									
11	124,056	1.00	reference	122	1.00	reference	227	1.00	reference
12-13	238,248	0.94	0.84 1.06	192	0.80	0.63 1.00	444	1.00	0.85 1.18
14	94,487	0.77	0.66 0.90	71	0.72	0.53 0.97	131	0.73	0.59 0.91
Oral contraceptive use									
Never	113,214	1.00	reference	72	1.00	reference	220	1.00	reference
Ever, 10 yrs ago	304,717	1.00	0.95 1.22	281	1.54	1.17 2.03	518	0.99	0.84 1.17
Ever, 5-10 yrs ago	17,513	1.34	1.00 1.80	16	1.95	1.10 3.46	25	1.08	0.70 1.66
Ever, within 5 yrs	23,408	1.37	1.05 1.80	16	1.51	0.85 2.69	41	1.38	0.96 1.98
Family history of breast cancer									
No	411,591	1.00	reference	331	1.00	reference	677	1.00	reference
Yes	47,269	2.42	1.57 3.36	54	1.39	1.04 1.86	127	1.55	1.28 1.88
Parity									
Nulliparous	85,033	2.75	1.02 8.84	51	0.71	0.48 1.07	156	1.17	0.90 1.52
1 birth	105,685	3.77	1.00 reference	91	1.00	reference	198	1.00	reference
2 births	134,026	4.49	0.93 0.81 1.07	131	1.09	0.83 1.43	228	0.90	0.74 1.09
3+ births	132,098	4.32	0.84 0.71 0.98	112	0.92	0.68 1.26	221	0.80	0.64 0.99
Age at first birth (yrs) ^d									
<20	125,426	3.97	1.00 reference	112	1.00	reference	200	1.00	reference
20-24	128,929	4.30	1.00 0.87 1.15	120	1.01	0.77 1.31	215	0.98	0.80 1.19
25	111,747	4.12	1.14 0.98 1.33	99	0.97	0.72 1.32	221	1.20	0.97 1.49
Years since last birth ^d									
10 yrs	350,948	1.198	1.00 reference	325	--	--	617	1.00	reference
<10 yrs	10,107	2.6	1.09 0.73 1.65	2	--	--	14	1.18	0.67 2.08
Lactation ^d									
Never	220,478	7.46	1.00 reference	202	1.00	reference	373	1.00	reference

	All invasive (n=1,534)				ER- (n=385)				ER+ (n=804)				
	person-years	cases	HR	95% CI	cases	HR	95% CI	cases	HR	95% CI	cases	HR	95% CI
Ever	145,885	497	1.04	0.93	1.18	128	1.01	0.80	1.27	266	1.12	0.95	1.32
BMI at age 18 (kg/m ²)													
<20	202,790	727	1.00	reference	191	1.00	reference	382	1.00	reference			
20–24	196,533	640	0.90	0.81	1.01	159	0.87	0.70	1.09	331	0.88	0.76	1.03
25	50,353	135	0.76	0.63	0.93	31	0.73	0.49	1.09	75	0.80	0.61	1.04
Current BMI (kg/m ²)													
<25	96,942	337	1.00	reference	84	1.00	reference	169	1.00	reference			
25–29.9	158,660	527	0.95	0.82	1.09	148	1.04	0.79	1.37	279	1.00	0.82	1.21
30	198,604	659	1.00	0.87	1.16	151	0.87	0.65	1.17	352	1.08	0.88	1.32
Waist:hip ratio													
Tertile 1 (<0.76)	105,204	324	1.00	reference	81	1.00	reference	167	1.00	reference			
Tertile 2 (0.76–0.84)	116,588	383	1.05	0.91	1.22	106	1.17	0.87	1.57	209	1.11	0.90	1.36
Tertile 3 (>0.84)	115,305	380	1.07	0.92	1.25	98	1.11	0.82	1.51	195	1.04	0.84	1.29
Alcohol consumption (drinks)													
<1/wk	317,121	1079	1.00	reference	274	1.00	reference	565	1.00	reference			
1–6/wk	118,361	376	0.94	0.83	1.06	90	0.90	0.71	1.15	203	0.96	0.82	1.13
7/wk	22,950	79	1.01	0.80	1.27	21	1.07	0.68	1.68	36	0.88	0.63	1.24
Vigorous exercise													
None	243,272	858	1.00	reference	223	1.00	reference	450	1.00	reference			
<5 hrs/week	178,581	562	0.94	0.84	1.04	134	0.83	0.67	1.04	297	0.95	0.82	1.10
5 hrs/week	33,355	103	0.94	0.76	1.16	26	0.88	0.58	1.33	51	0.92	0.68	1.23

* Multivariable hazards ratios (HRs) adjusted for age, smoking history (never active or passive, passive only, never active/unknown passive, 1–<10 packyears, 10+ packyears), menopausal status (premenopausal, hysterectomy only, postmenopausal age <40, postmenopausal age 40–44, postmenopausal age 45, postmenopausal age unknown or missing), postmenopausal hormone use (never, E+P <5 years duration, E+P 5+ years duration, other type), and all factors in Table 3.

^a Among parous women only. Estimates for age at first birth adjusted for age, smoking history, menopausal status, and all factors in Table 3 except years since last birth; estimates for years since last birth adjusted for age, smoking history, menopausal status, and all factors in Table 3 except age at first birth; estimates for lactation adjusted for age, smoking history, menopausal status, and all factors in Table 3.